Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs

South West
24 May 2013 17:14



North East London
24 May 2013 16:39



South and South West
24 May 2013 16:16


Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Joe Moore
Operations Director
joe@zenopa.com
+44 1494 818011

Testimonials
Thank you so much for your comprehensive efforts. I must admit it is a refreshing surprise to have such an informative response. I can assure you it is really appreciated.
Shan, 2013

Medtronic: Insulin pump therapy more effective than injections

5 December 2006 00:00 in Medical Company Product News


Medtronic has announced the results of a survey it commissioned carried out by GfK Roper Public Affairs regarding the use of insulin pump therapy as an alternative to standard insulin injections for the management of blood glucose levels.

The survey found that both endocrinologists and patients held that insulin pump therapy was a preferable treatment for blood glucose control than injections, with two-thirds of endocrinologists stating that they would choose that form of treatment for themselves or a family member.

Dr Bruce Buckingham, director of paediatric endocrinology at Lucille Packard Children's Hospital reported that hypoglycaemia was a "significant barrier" to the control of diabetes, despite the introduction of longer-acting insulin.

"Insulin pump therapy delivers insulin in patterns similar to how the body delivers insulin," he said.

"This decreases the risk of severe hypoglycaemic events ? allowing patients the flexibility to lead more active, normal lives," he added.

Earlier this week, Medtronic announced its intention to spin-off its external defibrillation business into a new company named Physio-Control. It estimated that this company would have sales of approximately $450 million (227.6 million pounds) in the next financial year.

The new publicly traded and independent company will offer both automated external defibrillators and manual defibrillators that are used by emergency response teams and in hospitals.

Other news stories from 05/12/2006

Recent news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd